Pfizer Painkiller Gets Longer Patent Protection
Pfizer could gain an additional 18 months of U.S. exclusivity—and monopoly sales—for its painkiller Celebrex because the government effectively reinstated a patent whose claims were previously struck down in court.
Tags:
Pfizer Painkiller Gets Longer Patent Protection,
Pfizer Latest News